Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

Alexion Pharmaceuticals said Wednesday it is buying Sweden’s Wilson Therapeutics for $855 million to expand its pipeline of drugs to treat rare diseases, as the pace of deal-making in the biotech sector ticks higher.